• Skip to primary navigation
  • Skip to main content
  • Skip to footer
ppi_logo_rgb_outlinedv3
address
  • Home
  • About
    • Introduction
    • PPi’s 20th Anniversary
    • The Strength of PPI HC
    • Our Mission
    • Global Reach
    • Customers
    • Team
    • Gallery
  • Services
    • Landscape Assessments
    • Market Access Strategy
    • Research and Insights
    • Pricing Strategy
    • Reimbursement Strategy
    • Health Technology Assessment dossiers
    • Health Economics
    • Orphan & Rare Diseases
  • Communications
    • Case Studies
    • Publications
    • Conferences
  • Contact
  • Home
  • About
    • Introduction
    • PPi’s 20th Anniversary
    • The Strength of PPI HC
    • Our Mission
    • Global Reach
    • Customers
    • Team
    • Gallery
  • Services
    • Landscape Assessments
    • Market Access Strategy
    • Research and Insights
    • Pricing Strategy
    • Reimbursement Strategy
    • Health Technology Assessment dossiers
    • Health Economics
    • Orphan & Rare Diseases
  • Communications
    • Case Studies
    • Publications
    • Conferences
  • Contact

Maximizing Rapid (!) Patient Access for Funded Usage of Innovative Orphan and Rare Disease Technologies

  1. Home>
  2. Maximizing Rapid (!) Patient Access>
White Paper

by Adam Barak MCIM
Global Genes: 2017 Rare Partnering Investors Forum;
September 14, 2017

Introduction

With such high levels of clinical unmet need, for technologies aimed at treating rare conditions the importance of getting these sometimes life-saving therapies to patients across the world as soon as possible is extremely important.

Oftentimes there are no or few available therapies for these conditions and so everything that can be done needs to be done to streamline the necessarily thorough and rigorous preparatory activities aimed at securing both payer/insurance funding and access.

This Paper for Global Genes 2017 focuses on two areas where we believe more can be done to facilitate this “Rapid Patient Access”, namely:

1. Understanding which work needs to be done to secure international market access (good funding, prices and formulary access) for a novel technology/drug in rare disease and

2. Understanding the international market priorities for a novel technology/drug in rare disease, including commercial market prioritization by region and country

Overview of Orphan Drug international regulations

The Orphan Drug Act of 1983 paved the way for the development of drugs that treat rare diseases. Orphan drugs (OD) can cost hundreds of thousands of dollars annually as with relatively small patient numbers, manufacturers are often obliged to charge higher than normal prices to recoup investment. Payers and insurers traditionally covered these therapies because the small populations involved did not typically lead to significant cost exposure. However payer sensitivity to the cost of ODs is rising due to the accelerated rate of new launches of these agents amid intensified general economic pressure on healthcare, resulting in payers showing increased levels of scrutiny about pricing and coverage for ODs.

Rare disease definitions

  • USA (1983) <200,000 cases
  • Europe (2000) <5 per 10,000
  • Japan (1993) 2.5 per 10,000
  • World Health 6.5-10 per 10,000

Organization

Globally some countries have concessionary pricing and reimbursement (P&R) and Health Technology Assessment (HTA) schemes for orphan and rare diseases (ORDs), e.g. the UK, Germany, Italy and France, but many do not so that securing special concessions for coverage of ODs is far from straightforward. Even in those markets that do have special approaches to ORDs, manufacturers will still need to ensure that appropriate value messages are substantiated and in line with technology’s pricing. Therefore to achieve good funding and access, early planning and payer engagement are essential.

Concessions and incentives to support the development of ODs include the following, but are generally based on pre-approval measures rather than post-approval concessions on payer evidence requirements or pricing.

  • Extended market exclusivity (7-10 years)
  • Tax and fee reductions (clinical trials, inspections, MAs)
  • Protocol assistance, free advice
  • Research grants
  • Central European filing / expedited regulatory review
  • Single format annual report to either FDA or EMA

Recent trends in OD funding

A fairly new development in the US, through Formulary Benefit Design (FBD), has seen patient share of OD costs rising and this is expected to continue. The shift in FBD could affect patient access to ODs and therefore drug utilization. Manufacturers will have to ensure to understand payer impact on the uptake of their ODs in development. They will also benefit from being better prepared to develop strategies to ensure patient access to and the affordability of their orphan agents.

US payers expect the management of ODs to intensify. Manufacturers, providers, and patients can expect the following strategies from insurers that administrate commercial and Medicare health plans:

  • Scrutiny of OD utilization where costs approach and exceeding the $50,000 per-patient per-year threshold
  • Increased focus on appropriate use of ODs, often restricting use to approved indications
  • Rising burden on patients through cost-sharing (i.e. co-insurance and higher co-payments), as well as existing annual or lifetime maximum payments.

In Europe many ODs receive differential funding across the region, where a drug can effectively be denied to patients in one country while patients in neighboring countries can receive it. An example is eculizumab (Soliris®) which although is reimbursed in many countries at >$100,000 / year, some countries have decided not to fund it, in this case the Authorities (NCPE in Ireland and TLV in Sweden) citing that it does not represent adequate value for money.

In many cases ODs initially denied reimbursement are subsequently granted it, following submission of further data or price negotiation. This inevitably means that some vital ODs can be denied to

patients for over a year. Such turnaround decisions have been seen with Jakavi® (ruxolitinib for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis) in Sweden and ivacaftor (Kalydeco® for cystic fibrosis) in Ireland.

Approaches for maximizing patient access for funded usage of innovative orphan and rare disease technologies

Given the circumstances described above of payers’ financial pressures and increasing rigor in assessing value and affordability of ORD treatments, we have cited 2 areas which OD manufacturers need to pay particular attention to if OD patient access is to be maximized.

1. Understanding which work needs to be done to secure international market access (good funding, prices and formulary access) for a novel technology/drug in rare disease

Oftentimes early clinical development focuses on regulatory requirements and milestones and not payer or access requirements. There is little point in investment and clinical studies targeted primarily to ensure that a drug is registered if the evidence does not support the commercial value of the drug (e.g. an appropriate price which payers will accept) and an evidence package which supports positive and quick formulary decision making.

Clinical studies therefore need to be designed that meet the requirements for ensuring rapid market access as well as approval, and work needs to be undertaken to establish which activities need to be conducted to similarly support rapid formulary access post approval in all countries of interest, as these activities invariably differ between countries and even sometimes between regions in the same country.

2. Understanding the international market priorities for a novel technology/drug in rare disease, including commercial market prioritization by region and country

Commercial decision making is driven often by forecasts of market potential in various countries, with activities being based for example on which are the largest markets, or the most familiar countries etc. Sometimes with ORDs the prevalence of conditions in different countries may not be known and in some genetic diseases, it is often seen that smaller population countries have a disproportionately high number of patients with a particular condition. Furthermore, some countries have formal and well-used schemes enabling the use of un-approved drugs (Early Access Schemes) in patient populations with high unmet need.

It is therefore important to derive good knowledge of international market potential and advance access arrangement schemes when designing clinical trials, resourcing staff and planning commercial activities so that patient populations can quickly be identified and actions undertaken to support access to the new therapies as soon as possible.

Maximizing rapid patient access to ODs

In order to try and maximize the chances for developed ODs securing favorable P&R and rapid patient access following regulatory approval, PPi HC has developed its “Checklist-20”, representing a breadth of activities that manufacturers and investors are advised to consider from early stage development onwards. The list is not exhaustive but aims to mitigate some of the issues described above (delayed access, inappropriate pricing, varied payer evidence requirements etc.) and does act as a useful guide

to the types of preparatory activities that should be conducted to support ORD patients receiving novel therapeutics as soon as possible.

ORD Market Access: Strategic Planning using “Checklist 20”

  1. Resourcing needs analysis including market access roadmap
  2. Pre-approval use (Early Access). Whether to provide it, how, where, when charging considerations etc.
  3. Landscape assessment (current status, treatment centers, Standard of Care etc.)
  4. Reimbursement data needs (clinical, economic, QoL etc)
  5. Payer research in n countries to explore value arguments and to inform the P&R strategy
  6. Physician research in n countries to explore value arguments, likely adoption and to inform the P&R strategy
  7. Identifying patient numbers per country
  8. Securing formal / informal payer guidance where available / required to inform clinical development programme
  9. Identify any patient access-supporting schemes that may be accessible or required (patient assistance programs, patient access schemes etc.)
  10. Explore specific ring-fenced funds for ORD reimbursement and how to access them
  11. Develop international pricing and reimbursement strategy
  12. Price and reimbursement submission (including submission / dossier preparation)
  13. HTA submission, including health economic modelling for those markets requiring it
  14. Securing codings and exemptions etc.
  15. Objection handler with supportive references
  16. National market entry guidance (central vs regional, hospital direct engagement etc.)
  17. Country prioritization and Launch sequencing strategy
  18. Identify / participate in relevant meetings
  19. Identify/ contact relevant treatment centers
  20. Identify / contact relevant associations (patient and professional)

Further reading

Orphan drugs: pricing, reimbursement and patient access

IJPHM, Volume 5, Number 4. 2011

Adam Barak & Jyoti Shankar Nandi

https://www.emeraldinsight.com/doi/abs/10.1108/17506121111190121?journalCode=ijphm

 

Publications

  • Adam Barak’s response to Sarah Bosely’s article printed in Guardian, 12th April 2018
  • Maximizing Rapid (!) Patient Access for Funded Usage of Innovative Orphan and Rare Disease Technologies
  • New UK PPRS Arrangements, 2014
  • Pricing policy in Europe: of cars, football, and prescription drugs
  • Orphan drugs: pricing, reimbursement and patient access
  • Paying the price
  • Caution: thresholds can sometimes be difficult to cross
  • UK PPRS Overhaul
  • Pharmaceutical pricing: Overview of the impact of genericisation
  • Pricing policies to handle patent loss or expiry

TESTIMONIALS

“With their depth of market access experience across the EU, Adam Barak and his team at PPi Healthcare are well-positioned to provide timely, insightful guidance on pricing and reimbursement. ProMetic’s global strategic launch plans involving ultra-orphan therapies, have been greatly enhanced by our collaboration with PPi.”

Kristine Dorward, Director, Marketing & Business Development, ProMetic Life Sciences Inc.

“I want to let you know that the feedback from my colleagues after your presentation was that they are impressed by the amount of information that you have gathered within the research within such a short period.”

Ramona Schmid, Global Market Access, Pricing and Reimbursement Manager, HRA Pharma

“I have worked with PPi on several projects and I will work with them again. The first project was a European pricing study for an orphan product. Having already completed one study with a competitor, I found the PPi team to be particularly insightful, having taken the time to completely understand this complex project.”

Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals

“Recently I completed an assessment to inform the collection of pharmacoeconomic data in a clinical study in the US and Europe. The team again were very insightful and we had unexpected value-added when we found a member of the PPi had been involved in the pricing and reimbursement activities relating to one of our comparables. Great team, great results!”

Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals

PPI Logo

Adding global value through local expertise and insight

Adding global value through local expertise and insight

PPi Healthcare Consulting Ltd
5 The Chambers, Vineyard
Abingdon-on-Thames
Oxfordshire
OX14 3PX, UK

Further information:
E: info@ppi.consulting
T: +44 (0)7811 363098

Privacy Policy

GEP

© copyright 2020
PPi Healthcare Consulting Ltd
All rights reserved

This website uses cookies to improve your experience. To view our privacy policy click here. To change your cookie preferences:Cookie settingsor ACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT